drugset / Trial / NCT03980249
Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells
Phase 0
Withdrawn
West Virginia University
NovoCure Ltd. · collabWest Virginia Clinical and Translational Science Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this pilot study is to evaluate the addition of carvedilol with standard of care treatment to determine if it will improve progression-free survival in the front line setting in patients with glioblastoma multiforme (GBM). In addition, monitoring of circulating tumor cells (CTCs) by a real-time reverse transcriptase polymerase chain reaction (qRT-PCR) assay to correlate with the clinical findings.
Timeline
- Start
- 2020-09
- Primary completion
- 2021-12
- Completion
- 2022-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carvedilol | Other / unclassified | 12.5 mg | Oral |